View Profile

General information

Company profile	fluidmobile GmbH has successfully eliminated a major innovation blocker in digital healthcare. Against cost explosions and lengthy project durations for regulatory-compliant therapy products, they have developed a solution: the mHealth Suite, a patient-centered health platform for digital therapy and homecare offerings. It standardizes application concepts, thus facilitating patient access. For companies in Pharma and MedTech, the mHealth Suite enables scalable digitization of their therapies into a market-ready digital product. Within 8 weeks, a single digital therapeutic can be developed to be CE-ready, available, and operational on the platform. Quality is ensured through development according to high European medical device standards and compliance with German data protection and security requirements for DiGAs.
Products & Services	mHealth Suite by fluidmobile 1) Patient-Centered Health Platform for Digital Therapies – Country-specific platform – Based on DiGA system best practices from Germany – Transfer of effective digital therapies for prioritized morbidities – Expanding range via digitization of market-dependent therapies and homecare (Digital Health/After Care/Blended Care) – User-friendly due to consistent usability – Optional marketplace for country-specific third-party providers 2) Digitization of Therapies and Medical Homecare Applications – CE-ready digital product in eight weeks – Includes development, maintenance, hosting per ISO 27001 – B2B white-label solution, individually configurable – Modular, indication-agnostic software technology – Compliance with MDR and GDPR – High standards for DiGAs in Germany – Scalability: horizontal (many different products) and vertical (rapid development and market adaptation)
References and export activities	Four years of expertise in client commissions with successful product development and international scaling of complex medical products, involvement in 6 indication-specific therapy applications as DiGA or DTx.
Target group	State health institutions, insurance companies, and hospitals as well as all therapy and homecare providers from Pharma and MedTech interested in digitizing health offerings with indication-specific mHealth products and Digital Therapeutics (DTx), in accordance with high European medical device standards and availability of offerings on a country-specific platform.
Competitive advantages	Patient-centered health platform for digital therapeutics, with app selection for country-specific morbidities based on the best practices of Digital Health Applications (DiGA) in Germany, and the offering to Pharma and MedTech companies on-site for the digitization and scaling of their therapy and homecare offerings on the platform in a short time and MDR-compliant. Optional marketplace for third-party providers.
Ideal Business Partners	We solve problems related to the challenges of digitizing health offerings with indication-specific mHealth/DTx apps (DTx: Digital Therapeutics). Our platform benefits state health institutions, insurance companies, and hospitals, as well as all therapy and homecare providers from Pharma and MedTech who want to quickly and MDR-compliantly convert their existing therapy concepts into digital products.